LIVER DISEASE – NON HEPATITIS also see HEPATITIS

 

HEMP AS A MEDICAMENT : Importance of hemp seeds in the tuberculosis therapy (Forum thread- full- 1955) (EDEZYME. recipe)  http://www.bushka.cz/KabelikEN/hempseed.html

 

Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.                                                            (abst – 2002)     http://www.ncbi.nlm.nih.gov/pubmed/12190187

 

A Novel Synthetic Cannabinoid Derivative Inhibits Inflammatory Liver Damage via Negative Cytokine Regulation                                                                           (full – 2003)  http://molpharm.aspetjournals.org/content/64/6/1334.full

 

The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis.                                                             (abst – 2003)  http://www.ncbi.nlm.nih.gov/pubmed/13679241

 

Pathogenesis and treatment of pruritus in patients with cholestasis                     (abst – 2003)

http://www.ncbi.nlm.nih.gov/pubmed/12664347

 

Treatment of the Pruritus of Cholestasis.                     (abst – 2004)

http://www.ncbi.nlm.nih.gov/pubmed/15527716

 

 

 

 

 

 

 

 

 

The endocannabinoid system in chronic liver disease              (full – 2005)

http://www.medigraphic.com/pdfs/hepato/ah-2005/ah054c.pdf

 

(Marijuana/Hash) Endocannabinoids and liver disease – review              (full – 2005)

http://www.natap.org/2005/HCV/091905_01.htm

 

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity                                              (full – 2005)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087161/?tool=pmcentrez

 

Roles of anandamide in the hepatic microcirculation in cirrhotic rats               (full – 2005)

http://ajpgi.physiology.org/content/290/2/G328.full?sid=c16d770d-cd17-48c9-bbde-26f38f5eeb67

 

The Ffa Receptor Gpr40 Links Hyperinsulinemia, Hepatic Steatosis, and Impaired Glucose Homeostasis in Mouse.                                                                 (abst – 2005)  http://www.ncbi.nlm.nih.gov/pubmed/16054069

 

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.              (abst – 2005)

http://www.ncbi.nlm.nih.gov/pubmed/15765409

 

CB2 receptors as new therapeutic targets for liver diseases              (full – 2007)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219531/?tool=pubmed

 

Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis

(full – 2007)                 http://www.jleukbio.org/cgi/content/full/82/6/1382

 

Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase   (full – 2007)                            http://hmg.oxfordjournals.org/cgi/content/full/14/22/3389

 

Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats   (full – 2007)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225474/?tool=pmcentrez

 

Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis (full – 2007)                            http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225476/?tool=pmcentrez

 

Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation                                                                         (full – 2007)  http://ajpgi.physiology.org/content/294/2/G506.full

 

Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury (full – 2007)                                   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228252/?tool=pmcentrez

 

Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.      (abst – 2007)                            http://www.ncbi.nlm.nih.gov/pubmed/17952109

 

 

 

 

 

 

 

 

 

Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis  (full – 2008)                              http://www.em-consulte.com/article/200095

 

CB2 receptors as new therapeutic targets for liver diseases.              (full – 2008)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219531/?tool=pubmed

 

Role of cannabinoids in chronic liver diseases               (full – 2008)

http://www.wjgnet.com/1007-9327/full/v14/i40/6109.htm

 

Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver (full – 2008)

http://ajpgi.physiology.org/content/294/1/G9.full?sid=872637e5-97b2-4103-aaf0-b3e8f6f0eb64

 

Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis   (full – 2008)  http://ajpgi.physiology.org/content/294/2/G357.full?sid=872637e5-97b2-4103-aaf0-b3e8f6f0eb64

 

Endocannabinoids and Liver Disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases                                                                  (full – 2008)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376822/?tool=pmcentrez

 

Endocannabinoids and Liver Disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis           (full – 2008)                             http://ajpgi.physiology.org/cgi/content/full/294/5/G1101

 

Endocannabinoids and Liver Disease. V. Endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis                                                      (full – 2008)  http://ajpgi.physiology.org/content/295/4/G649.full?sid=c16d770d-cd17-48c9-bbde-26f38f5eeb67

 

Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats            (full – 2008)  http://jpet.aspetjournals.org/content/324/2/475.full?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=  cannabinoid&searchid=1&FIRSTINDEX=320&resourcetype=HWCIT#content-block

 

Endocannabinoids and the Control of Energy Homeostasis             (full – 2008)

http://www.jbc.org/content/283/48/33021.full?sid=931583b1-e797-43e0-8296-7fd75bb49403

 

Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects     (abst – 2008)                           http://gut.bmj.com/content/57/8/1140.abstract

 

Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning          (full – 2008)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219536/?tool=pmcentrez

 

Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice.                                               (abst – 2008)        http://www.ncbi.nlm.nih.gov/pubmed/19086956

 

Endocannabinoids in liver disease and hepatic encephalopathy.              (abst – 2008)

 

 

 

 

 

 

 

 

http://www.ncbi.nlm.nih.gov/pubmed/18781986

 

The endocannabinoid system as a novel target for the treatment of liver fibrosis (abst – 2008)                                   http://www.ncbi.nlm.nih.gov/pubmed/17412522

 

Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects      (abst – 2008)                          http://gut.bmj.com/content/57/8/1140.abstract

 

Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis                                                                    (full – 2009)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688760/?tool=pubmed

 

Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology                                                                (full – 2009)  http://www.biomedcentral.com/1471-230X/9/75

 

Cannabinoids as novel anti-inflammatory drugs.              (full – 2009)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828614/?tool=pubmed

 

Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress.                                              (abst – 2009)  http://www.unboundmedicine.com/medline/ebm/record/19441010/abstract/

 

Science: Oral intake of a cannabinoid together with a meal improved bioavailability by avoiding first-pass metabolism                                               (abst – 2009)

http://www.cannabis-med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=291#2

 

The role of CB2 cannabinoid receptor and Leptin in hepatic fibrosis via lymphocyte alterations and HSC phagocytosis                                                 (abst – 2009)  http://www.docstoc.com/docs/76792678/The-role-of-CB2-cannabinoid-receptor-and-Leptin-in-hepatic-

 

Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. (abst – 2009)  http://www.unboundmedicine.com/medline/ebm/record/19596476/abstract/Cannabidiol_ameliorates_cogni tive_and_motor_impairments_in_mice_with_bile_duct_ligation_

 

Effect of (-)-Delta(9)-tetrahydrocannabinoid on the hepatic redox state of mice. (full – 2010)

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-  879X2010007500015&lng=en&nrm=iso&tlng=en

 

Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5- HT1A receptor activation.                                                         (full – 2010)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2829220/?tool=pubmed

 

Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.           (abst – 2010)                 http://www.ncbi.nlm.nih.gov/pubmed/20934397

 

Role of the endocannabinoid system in alcoholic liver disease.               (abst – 2010)

 

 

 

 

 

 

 

 

http://www.ncbi.nlm.nih.gov/pubmed/21525760

 

Endogenous cannabinoids in liver disease: Many darts for a single target              (abst – 2010)

http://www.ncbi.nlm.nih.gov/pubmed/19758727

 

Endocannabinoids in liver disease.               (full – 2011)

http://onlinelibrary.wiley.com/doi/10.1002/hep.24077/full

 

Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis.                                                              (full – 2011)  http://www.nature.com/cddis/journal/v2/n6/pdf/cddis201152a.pdf

 

Cannabidiol, a Major Phytocannabinoid, as a Potent Atypical Inhibitor for Cytochrome P450 2D6.         (full – 2011)

http://dmd.aspetjournals.org/content/early/2011/08/05/dmd.111.041384.long

 

Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                                   http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/

 

Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats. (abst – 2011)                                   http://www.ncbi.nlm.nih.gov/pubmed/21930120

 

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.                                                      (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21704641/abstract/Identification_of_cytochrome_   P450_enzymes_responsible_for_metabolism_of_cannabidiol_by_human_liver_microsomes_

 

Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and cell death                                                (abst – 2011)  http://www.fasebj.org/cgi/content/meeting_abstract/25/1_MeetingAbstracts/639.12?maxtoshow=&hits=80

&RESULTFORMAT=&fulltext=cannabinoid&searchid=1&FIRSTINDEX=160&sortspec=date&resourcet  ype=HWCIT

 

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver                                                          (abst  – 2011)  http://www.pnas.org/content/108/15/6323.abstract?maxtoshow=&hits=80&RESULTFORMAT=&fulltext=  cannabinoid&searchid=1&FIRSTINDEX=80&sortspec=date&resourcetype=HWCIT

 

Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating kupffer cell polarization in mice.                                                    (abst – 2011)      http://www.ncbi.nlm.nih.gov/pubmed/21735467

 

Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice.                                          (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/21182490

 

Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. (abst – 2011)

http://www.unboundmedicine.com/medline/ebm/record/21362471/abstract/Cannabidiol_protects_against_h

 

 

 

 

 

 

 

 

epatic_ischemia/reperfusion_injury_by_attenuating_inflammatory_signaling_and_response_oxidative/nitra   tive_stress_and_cell_death_

 

Δ(8) -Tetrahydrocannabivarin protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress and inflammatory response involving CB(2) receptors. (abst – 2011)           http://www.ncbi.nlm.nih.gov/pubmed/21470208

 

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver.                                                            (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21383171/abstract/Hyperactivation_of_anandamid

 

 

 

A new cannabinoid 2 receptor agonist HU-910 attenuates oxidative stress, inflammation, and cell death associated with hepatic ischemia/reperfusion injury.                                                         (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/21449982

 

Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/20597071/abstract/Beneficial_paracrine_effects_of

_cannabinoid_receptor_2_on_liver_injury_and_regeneration_

 

Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats. (abst – 2011)                                   http://www.ncbi.nlm.nih.gov/pubmed/21930120

 

Cannabis Compound Induces Death Of Cells Associated With Liver Fibrosis (news – 2011)                                         http://www.norml.org/index.cfm?Group_ID=8615

 

Marijuana Compound Improves Brain And Liver Function In Animal Model Of Hepatic Encephalopathy                                         (news – 2011)                http://www.norml.org/index.cfm?Group_ID=8464

 

Characterization of In Vitro Metabolites of CP 47,497, a Synthetic Cannabinoid, in Human Liver Microsomes by LC-MS/MS.                                                                (full – 2012)  http://onlinelibrary.wiley.com/doi/10.1111/j.1556-4029.2012.02261.x/full

 

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver                                                          (full – 2012)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076854/?tool=pubmed

 

Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.                                                        (abst – 2012)     http://www.ncbi.nlm.nih.gov/pubmed/22290687

 

Δ(8) -Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB(2) receptors.        (abst – 2012)                                http://www.ncbi.nlm.nih.gov/pubmed/21470208

 

The endocannabinoid 2-arachidonoylglicerol decreases calcium induced cytochrome c release from liver mitochondria.                                            (abst – 2012)  http://www.springerlink.com/content/54jm40088728t0pn/

 

 

 

 

 

 

 

 

 

Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems                                                                                   (abst – 2012)  http://jpet.aspetjournals.org/content/340/3/629.abstract?sid=ae58f15a-06bb-4a81-b850-61bb89fd59f5

 

Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic Fatty liver disease.                                                              (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22927922

 

Serum Metabolic Profiling Study of Hepatocellular Carcinoma Infected with Hepatitis B or Hepatitis C Virus by Using Liquid Chromatography-Mass Spectrometry.

(abst – 2012)                     http://www.ncbi.nlm.nih.gov/pubmed/22946841

 

Cannabidiol is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19. (abst – 2013)                                         http://www.ncbi.nlm.nih.gov/pubmed/23318708

 

Science/Animal: CBD inhibits the activity of a certain liver enzyme                      (news – 2013)  http://www.cannabis-  med.org/english/bulletin/ww_en_db_cannabis_artikel.php?id=391&search_pattern=2013#10

 

Share a link for